01-01-1970 12:00 AM | Source: ICICI Direct
Reduce Hester Biosciences Ltd For Target Rs.2780 - ICICI Direct
News By Tags | #872 #2894 #3961 #642 #1302

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

https://t.me/InvestmentGuruIndiacom

Download Telegram App before Joining the Channel

Weak poultry performance continues to weigh on numbers 

About the stock: Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzan

* It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products

* Revenue segment wise: poultry healthcare:73%, animal healthcare: 27%

Q1FY23 Results: Numbers weak as poultry farm economics turned adverse.

* Downgraded from HOLD to REDUCE due to adverse demand environment for poultry vaccines, slower ramp-up in Africa business, delay and uncertainty in execution of tenders along with dwindling margins

Target Price and Valuation: We value Hester at | 2015 (base business at | 1967 i.e. 38x FY24E EPS of | 51.8 + NPV of | 49 for Covaxin DS opportunity)

Key triggers for future price performance:

 * Opportunities in animal vaccines such as classical swine fever, lumpy skin disease (only player), sheep pox (only player) in the domestic space and expected launch of the modified Inactivated Coryza Vaccine, along with additional revenue from PPR national tender *

Increased focus on health products & widening of portfolio with differentiated herbal line of products looks promising for growth prospects

* Traction from manufacturing from Tanzania facility, Hester Africa and strengthened distribution network in Africa, along with increase in bulk antigen capacity and fill finish line for animal vaccines

* Foray into pet care with 11 products and new marketing teams in four zones

Alternate Stock Idea: Apart from Hester, in our healthcare coverage we like Indoco.

* Indoco manufactures and markets branded formulations and APIs for the domestic and export markets.

* BUY with target price of | 525 

 

To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 

Above views are of the author and not of the website kindly read disclaimer